Great news from the FDA! They have approved the first targeted drug for advanced stomach cancer. The drug, ramucirumab, used in the REGARD clinical trial, increased the median overall survival of patients with advanced stomach cancer by 37 percent. Researchers are now looking into whether a combination of ramucirumab and chemotherapy can give even better results. To see the full press release from Dana-Farber go to: http://www.dana-farber.org/Newsroom/News-Releases/fda-approves-first-targeted-drug-for-advanced-stomach-cancer.